Circulating soluble receptor for advanced glycation end products and other factors in type 2 diabetes patients with colorectal cancer

Autor: Xiaoling Wang, Bo Li, Qing Su, Peng Du, Xiaohai Zhou, Mingjie Zhang, Ye An, Hanbei Chen, Ning Lin
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Blood Glucose
Male
0301 basic medicine
medicine.medical_specialty
Colorectal cancer
Endocrinology
Diabetes and Metabolism
Receptor for Advanced Glycation End Products
Type 2 diabetes
Gastroenterology
lcsh:Diseases of the endocrine glands. Clinical endocrinology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Insulin resistance
Diabetes mellitus
Internal medicine
medicine
Humans
Risk factor
Aged
Colorectal Cancer
Soluble receptor for advanced glycation end-products
lcsh:RC648-665
Triglyceride
business.industry
General Medicine
Middle Aged
Prognosis
medicine.disease
Cross-Sectional Studies
030104 developmental biology
Diabetes Mellitus
Type 2
chemistry
030220 oncology & carcinogenesis
Homeostatic model assessment
Female
Colorectal Neoplasms
business
Biomarkers
Dyslipidemia
Follow-Up Studies
Research Article
Zdroj: BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Endocrine Disorders
ISSN: 1472-6823
Popis: BackgroundRecent study showed that individuals with type 2 diabetes have a high risk of developing colorectal cancer (CRC), in which Receptor for Advanced Glycation End Products (RAGE) plays a pivotal role. We conducted a cross-sectional study to examine the relationships of circulating sRAGE, CRC and other clinical factors in type2 diabetes patients.MethodsA total of 150 type 2 diabetes patients aged 50 years and older were enrolled, including 50 patients with CRC and 100 patients without CRC. We measured Serum levels of sRAGE and interleukin-6(IL-6) using an enzyme-linked immunosorbent assay (ELISA). In addition, other clinical parameters were also measured during hospitalization.ResultsType 2 diabetes patients with CRC had higher triglyceride, total cholesterol, IL-6, and circulating sRAGE levels and lower use of medicines than type 2 diabetes patients without CRC. Circulating sRAGE was associated with an increased risk for CRC (OR = 2.289 for each SD increase in sRAGE, 95% CI = 1.037–5.051;P = 0.04) among Type 2 diabetes patients after adjustment for confounders. Furthermore, circulating sRAGE levels among type 2 diabetes patients were positively correlated with triglyceride (r = 0.377,P r = 0.491,P r = 0.330,P r = 0.194,P = 0.017); and fasting serum insulin (r = 0.167,P = 0.041) and IL-6 (r = 0.311,P ConclusionsOur results suggested that circulating sRAGE is independently risk factor for CRC, and also closely related to inflammation, dyslipidemia in type 2 diabetes patients.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje